- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02847559
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine progression free survival (PFS) for 6 months (PFS-6) in patients with recurrent or progressive meningioma.
SECONDARY OBJECTIVES:
I. To determine overall survival (OS). II. To determine tumor response rate (TRR). III. To assess quality of life with treatment (QOL) using Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire.
OUTLINE:
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Suspended
- USC Brain Tumor Center
-
Santa Monica, California, United States, 90404
- Recruiting
- John Wayne Cancer Center at Providence St. John's Health Center
-
Contact:
- Santosh Kesari, MD, PhD
- Phone Number: 310-829-8265
-
Stanford, California, United States, 94305
- Not yet recruiting
- Stanford Cancer Center Neuro-Oncology Clinic
-
Contact:
- Seema Nagpal, MD
- Phone Number: 650-498-6000
- Email: snagpal@stanford.edu
-
-
Florida
-
Miami, Florida, United States, 33176
- Recruiting
- Miami Cancer Institute
-
Contact:
- Minesh P. Mehta, MD
- Phone Number: 786-596-2000
-
Principal Investigator:
- Minesh P. Mehta, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Recruiting
- Piedmont Healthcare
-
Contact:
- Erin Dunbar, MD
- Phone Number: 404-605-2050
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Sub-Investigator:
- Karan Dixit, MD
-
Principal Investigator:
- Priya Kumthekar, MD
-
Contact:
- Priya Kumthekar, MD
- Phone Number: 312-503-1818
- Email: p-kumthekar@northwestern.edu
-
Sub-Investigator:
- Jeffrey Raizer, MD
-
Sub-Investigator:
- Orin Bloch, MD
-
Sub-Investigator:
- James P. Chandler, MD
-
Lake Forest, Illinois, United States, 60045
- Active, not recruiting
- Northwestern University- Lake Forest Hospital
-
Winfield, Illinois, United States, 60190
- Recruiting
- Northwestern Medicine/ Cadence Health - CDH
-
Principal Investigator:
- Sean Grimm, MD
-
Contact:
- Sean Grimm, MD
- Phone Number: 630-352-5450
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Not yet recruiting
- Regions Hospital - Cancer Care Center
-
Contact:
- Richard A. Peterson, MD
- Phone Number: 651-254-3572
- Email: Richard.A.Peterson@HealthPartners.Com
-
Principal Investigator:
- Richard A. Peterson, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Arati S. Desai, MD
- Phone Number: 215-615-5858
-
Principal Investigator:
- Arati S. Desai, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)
- Patient's tumor must have a supratentorial component
- Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
All patients must have developed recurrent disease/progression (evidence of recurrence to be established by MRI or CT scan with contrast; there is no limit to the number of relapses) after receiving all standard treatments, which must include the following:
- Surgical resection, if possible;
- Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection (Note: At registration, patients must be at least 28 days post-surgery, and must be at least 28 days post-radiation therapy, with resolution of related cytotoxicities down to grade 2)
- Patients may have had previous systemic treatment regimens with the exception of bevacizumab (no limit to number of prior therapies); a 4 week wash-out period prior to registration is mandatory for all systemic treatments
- Life expectancy of at least 12 weeks
- Karnofsky performance status >= 60%
- Patients must have adequate bone marrow, kidney, and liver function, (within 14 days prior to registration), defined as:
- Absolute neutrophil count (ANC) >= 1500/uL (with/without growth factor)
- Hemoglobin (Hgb) >= 9 g/dL (with/without transfusion)
- Platelets >= 100,000/L
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
- Total bilirubin =< 1.5 x institutional ULN
- Serum creatinine =< 1.5 x institutional ULN
- Females of child-bearing potential (FOCBP) and males with partners of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study treatment; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; likewise, if the female partner of a male patient becomes pregnant or suspect she is pregnant, he should inform his treating physician immediately
NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy
Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
- FOCBP must have a negative serum or urine pregnancy test within 14 days prior to registration on study
- Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
- Patients must be able to comply with all protocol requirements
Exclusion Criteria:
- Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
- Patients who have had minor surgical procedures (with the exception of the placement of porta cath or other central venous access) within 7 days prior to registration
- Patients with infratentorial disease and spinal disease
- Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)
- Patients may not receive any other anti-cancer therapies, within 28 days prior to registration and throughout the duration of this trial
- Previous treatment with bevacizumab
- Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligible
- Patients with active implanted medical device, a skull defect (such as, missing bone with no replacement), a shunt or bullet fragments; examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts
- Patients with known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes
- Patients with proteinuria within 14 days of registration as demonstrated by either: urine protein creatinine (UPC) ratio >= 1.0 at screening OR urine dipstick for proteinuria 2+ (patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate =< 1 g of protein/24 hours to be eligible)
- Patients with a serious non-healing wound, active ulcer, or untreated bone fracture
- Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- Patients with history of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) within 28 days prior to registration
- History of myocardial infarction or unstable angina within 6 months of registration
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and /or diastolic blood pressure > 100 mmHg)
- History of stroke or transient ischemic attack within 6 months prior to registration
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- History of abdominal fistula or gastrointestinal perforation within 6 months prior to registration
- Chronic, systemic treatment with immunosuppressive agents; patients who require a stable dose of corticosteroids for control of cerebral edema are eligible; topical or inhaled steroids are also allowed
Patients who have any severe and/or uncontrolled intercurrent medical conditions including, but not limited to any of the following, are not eligible:
- Ongoing or active wound infection requiring concurrent systemic antibiotic treatment; there is no mandatory duration of time that a patient has to be off antibiotics, but the treating physician has to deem the infection as effectively treated prior to enrollment
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia (New York Heart Association [NYHA] criteria)
- Psychiatric illness/social situations that would limit compliance with study requirements, prevent patient comprehension of the nature of, and risk associated with, the study
- Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
- Female patients who are pregnant or nursing are not eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (bevacizumab, electric field therapy)
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4.
Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule.
Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Undergo electric field therapy using Optune device
Undergo electric field therapy using Optune device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival for 6 months (PFS-6)
Time Frame: At 6 months
|
Determine the efficacy of combination therapy of bevacizumab and Optune (TTF) as assessed by Progression Free Survival at 6 months
|
At 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: From time of registration to death, assessed up to 2 years
|
OS will be defined from the time of registration to death and will be assessed for up to 2 years.
|
From time of registration to death, assessed up to 2 years
|
Tumor Response Rate (TRR)
Time Frame: At baseline and every eight weeks, assessed up to 12 months
|
Imaging (MRI or CT scan) will assess radiographic response in terms of complete response, partial response, stable disease, and progressive disease.
The iRANO criteria will be used for response assessment.
|
At baseline and every eight weeks, assessed up to 12 months
|
Quality of Life (QOL) with treatment using FACT-Br questionnaire
Time Frame: At baseline, on Day 1 of every cycle, and 1 month after the last dose of study drug
|
To assess QOL with treatment the Functional Assessment of Cancer Therapy-Brain version 4.0 (FACT-Br) questionnaire will be administered.
|
At baseline, on Day 1 of every cycle, and 1 month after the last dose of study drug
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priya Kumthekar, MD, Northwestern University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Recurrence
- Meningioma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibodies
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Immunoglobulin G
- Endothelial Growth Factors
Other Study ID Numbers
- NU 16C02 (Other Identifier: Northwestern University)
- P30CA060553 (U.S. NIH Grant/Contract)
- STU00203030 (CTRP (Clinical Trial Reporting Program))
- NCI-2016-01026 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Meningioma
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
Central Hospital, Nancy, FranceUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMeningioma | Anaplastic Meningioma | Meningioma AtypicalItaly
-
Central Hospital, Nancy, FranceInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...RecruitingMeningioma AtypicalItaly
-
Rabin Medical CenterUnknownHemangiopericytoma | Atypical Meningioma | Anaplastic MeningiomaIsrael
-
Beijing Sanbo Brain HospitalRecruitingRecurrent Atypical/Malignant MeningiomaChina
-
Second Affiliated Hospital, School of Medicine,...Ningbo Medical Center Lihuili Hospital; Sir Run Run Shaw Hospital; Zhejiang Provincial... and other collaboratorsNot yet recruitingRadiotherapy | Meningioma Atypical | Adverse Effect of Radiation Therapy | Progression-Free Survival
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
National Cancer Institute (NCI)RecruitingEpendymoma | Medulloblastoma | Pineal Region Tumors | Choroid Plexus Tumors | Atypical/Malignant MeningiomaUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States